The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Nevertheless, GSK R&D chief Hal Barron thinks the triple therapy is still on track for a regulatory filing in uncontrolled asthma once the full dataset is available, and that could extend Trelegy ...

Infections should be treated with appropriate local or systemic antifungal therapy while remaining on Trelegy Ellipta, though Trelegy Ellipta may need to be interrupted in some cases. Patients ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can cause side effects that range from mild to serious. More common side effects include headache and ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

No major differences in adverse effects were observed between these inhalers and their alternatives. Trelegy Ellipta, a ...

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to ...

The cost of Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can vary based on several factors, including your insurance coverage. Coupons and drug savings ...